

March 25, 2025
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President & Chief Executive Officer
 (Securities Code: 4582)

Notice of Appointments to the Board Directors and Substitute Member of the Audit & Supervisory Committee, and Appointments of Corporate Officers

TOKYO, Japan, March 25, 2025 - Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced appointments to its Board Directors (excluding directors who are members of the Audit & Supervisory Committee), Board of Directors who are members of the Audit & Supervisory Committee and one Substitute Member of the Audit & Supervisory Committee made by resolution of shareholders approved at the 20th Annual General Meeting of Shareholders (the “AGM”), and Representative Director and Corporate Officer appointments approved by the Board of Directors at a board meeting convened following the close of the AGM. The appointments are as follows:

1. Board Directors (excluding directors who are Audit and Supervisory Committee members)

Name	Title
Fuminori Yoshida	Representative Director
Shigetoshi Matsumoto	Board Director <Outside>
Bruce David Cheson	Board Director <Outside>
Eiji Ebinuma	Board Director <Outside>
Toshio Imabeppu	Board Director <Outside>
George Morstyn	Board Director <Outside>
Ralph Smalling (newly appointed)	Board Director <Outside>

2. Board Director who is a member of Audit & Supervisory Committee

(Of the three Board Directors who are members of Audit & Supervisory Committee, one is newly appointed.)

Name	Title
Koichi Shimomura (newly appointed)	Board Director, Audit & Supervisory Committee Member <Outside>

3. Substitute Board Director who is a member of the Audit & Supervisory Committee

Name	Title
Takashi Watanabe	Substitute Board Director, Audit & Supervisory Committee Member <Outside>

4. Corporate Officers

Name	Title
Fuminori Yoshida	President and Chief Executive Officer
Masaru Taguchi	Corporate Vice President, Chief Operation Officer
Takaaki Fukushima	Executive Corporate Officer, Chief Financial Officer
Paul Marston	Corporate Officer, General Counsel
Koji Fukushima	Corporate Officer, Deputy Chief Medical Officer
Masatoshi Hazama (newly appointed)	Corporate Officer, Chief Scientific Officer

The biographies of the two new directors and a corporate officer are as follows:

New Director	Ralph Smalling	
Career	Jun. 1995	Regulatory Affairs Director, Amgen Inc. (USA)
	Jun. 2000	Vice President, Regulatory Affairs and International Clinical Safety
	Jun. 2003	Vice President, Global R&D Policy and Analysis
	Aug. 2005	Principal Consultant, Linus Consulting LLC (USA) (Concurrent)
	Jan. 2006	Lecturer, Channel Islands, California State University (USA)
	Jun. 2006	Board of Director, Direct Access Residential Energy (USA)
	Jul. 2023	Vice President, Head of Regulatory Affairs, Genelux Corporation (USA) (Concurrent)
	Mar. 2025	SymBio Pharmaceuticals Board Director

New Director	Koichi Shimomura	
Career	Apr. 1982	Joined Japan Petroleum Exploration Co., Ltd.
	Jul. 2006	Public Relations & Investor Relations Head
	Jun. 2011	Canada Oil Sands Project Division Head, Americas and Russia Project Division
	Jun. 2012	Assistant to Head of Americas and Russia Business Unit
	Jun. 2018	Full-time Audit & Supervisory Board Member
	Jun. 2022	Full-time Audit & Supervisory Board Member, Japex Offshore Ltd.
	Jan. 2024	Head of Legal Office, HW ELECTRO Co., Ltd.
	Mar. 2025	SymBio Pharmaceuticals Board Director

New Corporate Officer	Masatoshi Hazama	
Career	Apr. 1986	Joined Takeda Pharmaceutical Co., Ltd.
	Oct. 1999	Chief Researcher, Drug Discovery Research Institute I
	Mar. 2009	Director, Pharma Research Division, Cardiovascular/Metabolic Drug Discovery
	Aug. 2013	Senior Director, Extra Value Drug Discovery Unit
	Apr. 2017	Senior Director, Innovation & Entrepreneurship
	Oct. 2018	Joined SymBio Pharmaceuticals as Head of Translational Research, Development Division
	Oct. 2022	CSO (Chief Scientific Officer), Head of Translational Research, Development Division
	Mar. 2025	Corporate Officer and Chief Scientific Officer, Head of Translational Research, Development Division

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125